SCHEMBL16245559

SCHEMBL16245559

CCOC(=O)CCCOc1ccc(Nc2nc(Cl)ncc2N)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYSLTR2 Q9NS75 1/20 0.44
▸ CYSLTR1 Q9Y271 1/20 0.44
▸ CNR1 P21554 1/20 0.44
▸ MAPT P10636 3/20 0.44
▸ LMNA P02545 1/20 0.44
▸ SYK P43405 1/20 0.43
▸ P2RX3 P56373 2/20 0.43
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ P2RY12 Q9H244 1/20 0.42
▸ PABPC1 P11940 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ AURKA O14965 1/20 0.41
▸ LTA4H P09960 2/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ XDH P47989 1/20 0.40
▸ FAAH O00519 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ BRD4 O60885 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16245555 0.97 P2RX3 (0.44) CYSLTR2CYSLTR1CNR1MAPTLMNA
SCHEMBL18869374 0.86 JAK2 (0.44) CYSLTR2CYSLTR1CNR1MAPTLMNA
SCHEMBL16264828 0.86 EGFR (0.45) SYKP2RX3TDP1AURKAXDH
SCHEMBL16264830 0.86 EGFR (0.45) SYKP2RX3TDP1AURKAXDH
SCHEMBL16012129 0.85 SYK (0.44) MAPTLMNASYKTDP1ALDH1A1
SCHEMBL16245543 0.84 PIN1 (0.54) CYSLTR2CYSLTR1CNR1MAPTLMNA
SCHEMBL18869322 0.84 P2RX3 (0.43) CYSLTR2CYSLTR1CNR1MAPTLMNA
SCHEMBL16245532 0.81 PIN1 (0.53) CYSLTR2CYSLTR1CNR1MAPTLMNA
SCHEMBL17827716 0.80 SYK (0.57) MAPTSYKALDH1A1KDM4E
SCHEMBL16012041 0.79 SYK (0.44) SYKKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
US-9861635-B2 Macrocycles as kinase inhibitors MERCK PATENT GMBH (DE) 2018-01-09 — — US disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
EP-2994471-B1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2017-05-17 — — EP disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2016-06-16 — — US disclosed
EP-2994471-A1 MACROCYCLES AS KINASE INHIBITORS Merck Patent GmbH (DE) 2016-03-16 — — EP disclosed
WO-2014180524-A1 MACROCYCLES AS KINASE INHIBITORS MERCK PATENT GMBH (DE) 2014-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166574-A1 MACROCYCLES AS KINASE INHIBITORS EIF2AK4, CDK2, CDK1 CYSLTR2 2472/4885CYSLTR1 3194/4885CNR1 3487/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback